NAD+ Benefits and Side Effects: What Human Studies Have Found
What the human trials report for NAD+ and its precursors, on benefits and on side effects, and where the gaps are.
Words by the editors ·
Short answer: human trials show that NAD+ precursors raise NAD+ in the blood and are generally well tolerated over weeks to months, but proven health benefits are few, and long-term safety is unknown. Reported side effects of oral forms include muscle pain, fatigue, sleep disturbance and headache, and intravenous NAD+ has been linked to nausea, cramping, flushing and chest discomfort.24 This page goes through what was measured, in whom, and what that does and does not mean.
For background, see our explainer What Is NAD+? and our look at whether NAD+ supplements are worth it.
In brief
- In an 8-week trial of 100, 300 and 1,000 mg of nicotinamide riboside, whole-blood NAD+ rose 22%, 51% and 142%, with no significant difference in adverse events from placebo.1
- A systematic review of 10 randomized trials (489 people) found NADH and precursors were well tolerated; every study reported some side effects, most often muscle pain, nervous disorders, fatigue, sleep disturbance and headache.2
- A 10-week trial in postmenopausal women with prediabetes found NMN raised muscle insulin sensitivity; it did not test men or healthy adults.3
- For intravenous NAD+, a 2026 review reports nausea, cramping, flushing and chest discomfort, calls the evidence preliminary and says long-term safety data are lacking.4
What are the benefits of NAD+?
NAD+ is a coenzyme involved in turning food into usable energy, DNA repair and stress signaling, which is why it attracts interest.4 Animal studies of NAD-boosting molecules have been encouraging.5 The question for readers is what has been shown in people, and the answer is narrower.
The firmest result is biochemical. In an 8-week randomized, placebo-controlled trial in overweight but otherwise healthy adults, nicotinamide riboside (NR) at 100, 300 and 1,000 mg raised whole-blood NAD+ by 22%, 51% and 142%, and the rise held through the study. The manufacturer funded the trial.1
Health outcomes are less clear. In a 10-week randomized trial of postmenopausal women with prediabetes who were overweight or obese, nicotinamide mononucleotide (NMN) increased muscle insulin sensitivity and insulin signaling. The trial studied women of a specific profile, so it does not tell us the same would happen in men or in healthy adults.3 A 6-week crossover trial in healthy middle-aged and older adults found NR well tolerated and raised NAD+ metabolism, and its authors suggested future trials look at blood pressure and arterial stiffness, without claiming a proven effect.6
A 2025 meta-analysis of NMN and NR for skeletal muscle looked at whether raising NAD+ translates into muscle mass or function.7 We cover that in more depth in the supplements guide above. On fatigue, a 58-person trial in long-COVID found NR raised NAD+ about 2.6- to 3.1-fold but did not significantly improve fatigue against placebo.8
What are the side effects of NAD+?
A 2024 systematic review pooled 10 randomized trials with 489 participants, covering NADH and precursors in conditions from chronic fatigue syndrome to Alzheimer's disease. It found the products well tolerated. All studies reported some side effects, and the most common were muscle pain, nervous disorders, fatigue, sleep disturbance and headaches. The reviewers say none of the adverse events recorded posed a serious risk to participants.2
In the NR dose trial, adverse events did not differ significantly between NR and placebo groups or among doses, there were no reports of flushing, and LDL cholesterol did not rise.1
Intravenous NAD+ is a different route with a different profile. The 2026 narrative review reports nausea, cramping, flushing and chest discomfort, and says long-term safety data are lacking.4
| Form | Reported benefit | Reported side effects |
|---|---|---|
| Oral NR | Raised blood NAD+; no significant fatigue benefit in long-COVID18 | No significant difference from placebo in an 8-week trial1 |
| Oral NMN | Raised muscle insulin sensitivity in women with prediabetes3 | Reviewed together with other forms2 |
| NADH and mixed forms | Mixed outcomes in small trials2 | Muscle pain, fatigue, sleep disturbance, headache2 |
| Intravenous NAD+ | Preliminary; mostly small uncontrolled studies4 | Nausea, cramping, flushing, chest discomfort4 |
Do NAD+ levels really decline with age?
The usual pitch assumes older adults are low in NAD+. The 2026 review points out that recent large human datasets show whole-blood NAD+ does not decline with healthy aging on its own.4 Tissue levels can differ from blood levels, so this is not the last word, but it means that raising a blood number is not the same as fixing a deficiency.
What do we not know yet?
Most trials are short, small and often funded by the makers of the ingredient. Few track people for a year or more. The reviewers of intravenous NAD+ call the evidence preliminary and insufficient to support routine wellness use, and say larger randomized trials are needed.4 We found no trial that compares injections with oral forms, so any claim that one is safer or more effective is unsupported. Our review of the evidence on injections and energy goes into that gap.
Who should check with a clinician first?
Anyone who takes medicines or has a health condition should ask a prescriber before starting an NAD+ product. Compounded NAD+ injections are not FDA-approved, and the FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.9 Supplements are sold under a different set of rules from drugs, so the amount of active ingredient can vary by product.
A fair summary for a reader deciding is this: the side effects reported so far are mostly mild, the benefits beyond a higher blood NAD+ number are not yet established, and the long-term picture is empty. That is a reasonable basis for curiosity and a poor one for expecting results.
Questions
What are the benefits of NAD+?
The reliable finding is that precursors such as nicotinamide riboside raise blood NAD+ in people. Evidence of a health benefit is narrower: one trial found improved muscle insulin sensitivity with NMN in postmenopausal women with prediabetes, and larger trials have not shown a consistent effect on fatigue.
What are the side effects of NAD+?
In a systematic review of 10 randomized trials, the most common were muscle pain, nervous disorders, fatigue, sleep disturbance and headaches, and none was judged a serious risk. Intravenous NAD+ has been linked to nausea, cramping, flushing and chest discomfort.
Is NAD+ safe to take long term?
Long-term safety is not established. A 2026 review of intravenous NAD+ says long-term safety data are lacking, and the trials of oral precursors in this article ran weeks to months.
Do NAD+ levels really fall with age?
A 2026 review notes that recent large human datasets show whole-blood NAD+ does not fall with healthy aging by itself, which weakens the assumption that every older adult is low.
Who should be careful with NAD+ products?
Anyone taking medicines or with a health condition should ask a clinician first. Compounded NAD+ injections are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality.
Also in this edition
Part of our guide: Aging Well: NAD+, Exercise and the Male Body After 40
Notes
- Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019. PubMed 31278280.
- Gindri IM, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab. 2024. PubMed 37971292.
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed 33888596.
- Alangari A, et al. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Front Aging. 2026. PubMed 42787547.
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018. PubMed 29514064.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018. PubMed 29599478.
- Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025. PubMed 40275690.
- Wu CY, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025. PubMed 41357333.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.